News Novo Nordisk sheds billions in value on obesity data Novo Nordisk data on obesity candidate CagriSema falls short of expectations, wiping around $94 billion off its market valuation.
News Novo completes $16.5bn takeover of Catalent Novo Holdings' $16.5bn takeover of US CDMO Catalent has been completed, after months of debate over potential antitrust issues.
News Novo sets aside $1.2bn for rare diseases plant Novo Nordisk has started building its first brand-new manufacturing facility in Denmark this century and will spend around $1.2bn on the plant.
News Novo’s $16.5bn Catalent deal cleared by EU Commission EU says Novo Holdings’ $16.5 billion takeover of US contract development and manufacturing organisation Catalent does not pose antitrust issues.
News Zepbound tops Wegovy in first head-to-head weight-loss trial Eli Lilly is playing catch-up to Novo Nordisk in the fast-growing obesity therapy sector but has new data that could tip the balance in its favour.
News Novo sheds kidney drug licensed for $1.3bn a year ago Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.
News Regeneron swoops on genetic testing firm 23andMe DNA testing company 23andMe looks destined to be taken over by a pharma company, as Regeneron agrees a $256 million acquisition deal.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
